morning, thank you for Thanks, good Bioventus. interest Dave; everyone, in and continued and your
As successfully long-term to we completed finish Earlier we the continue a Bioness. build for year, of integration year, the foundation we the sustainable in growth.
completed In which we recently transformational schedule with integrations and addition, provides with the long-term on acquisition of CartiHeal, growth. accelerate are to Misonix us a of the opportunity
our we target of XXXX. integration, $XX achieve Misonix synergies the by million on are goal to in the of With end
We and are our And to more toward to the and way efficient we focused proud strengthening us our goals. our achieving team execution on make are strive of processes internal our global long-term outlook. continues improving
financial Our expectations the to these quarter results updating the we are during revenue quarter. the business results our and our fell full financial year expected guidance reflect below to for our impacts fourth and and
organic growth on impacts was for will detail. and currency well X%. our EBITDA in adjusted million revenue lower-than-expected rate For $XXX was the revenue for increased as the Organic gross to which as third X% impacts the XX% $XX after result more quarter Mark million. Adjusted margin, temporary of adjusting exchange was growth of constant quarter, discuss
Gelsyn. headwinds Gelsyn, resulted Medicare of greater-than-expected as two We changes primarily end the attributed that buying specific patterns changes as our announced face be headwinds revenue customer three-injection can HA to quarter shortfall due in quarter transitory well across HA our in entire the by volatility in to to portfolio. Our therapy, the to related primary reimbursement near
reporting. prior claims due their payer private who a in these higher-than-normal period The was rebate claims found errors from rebate first to earlier of unexpected charges
claims rebate with to an working are effort of in their reporting avoid payer We this volatility. private future on
The from in ASP, or change acquisition price, pricing second to or WAC. average cost, the was in selling recent HA market wholesale the to related impact
Importantly, rebates to as start deduction paid effect the last I negotiated payer be This the some our due on of of price now a the preferred took contracts. the and mentioned of quarter, change successfully ASP. decrease selling amount offsetting is at changed in we the in quarter the have to
more to Gelsyn beyond was ASP we the sales However, the as volume quarter the that non-contracted experienced due as shifted arose. accounts market quarter, expectations pricing during in volatility to price-sensitive our or during disadvantages change
the resolve XXXX, to While takes of of pricing expect issue pressure the and more will believe effect ASP full continued that mechanics reporting a position. see reporting Gelsyn as Gelsyn stabilizes we this on first competitive half we to revenue through ASP
reporting ASP based back. four-quarter reminder, a a look As is on
both strategy, our HA the as While growth to increased with segment continues moved further pricing, Durolane from And fastest-growing and customers Durolane, HA share the WAC which of with the this the that double-digit access molecular Durolane market market. dynamic possesses highest ASP not impact strong quarter. which in market coupled resonate any HA we did is differentiation, Gelsyn product. to of clinical for single-injection therapy our maintained weight
which as In the Gelsyn, quarter. portfolio they awaited we at middle pricing broader lower customers resulting delayed quarterly reset factors experienced our also impacting last the of these some HA ASP across our at the the to month of happens the the potentially purchases in end addition volatility from quarter, while of
and build quarter-to-quarter can on access highest favorably leader our We believe four near-term that factors the these market less changes HA our confident next shift share are distinct expect track share across on quarters. to as against market we few position impact We portfolio, ASP are the two become Number volatile take decreasing Despite competition. us the given strategy position. overall one, our become with to HA we Number number over any HA injection our continue and among payer molecular and competition. market category challenges, we longer the on pricing from the HA three number HA therapies quarter we in the market prescribing preferred base complete in the specific knee in portfolio market. market, unique the exclusive in have the of the five on is focused with customer our one, our the two, time therapy. our weight possesses space, largest product single providing them clinical four, Durolane force And fastest-growing the contracts. residence Number we sales differentiation of and three, injection
strong delivered disappointed high our execution that we achieved organic solutions our are restorative continue and injectable driven below substitute we surgical allograft, across therapies results double-digit steady Flowable, its hospital last introduction to solution, verticals. we and grow improved. our bone While OsteoAMP as total organic a growth was company rapidly single-digit issues by year. strong solutions, we growth, surgical recovery continues target, procedures as growth graft double-digit to see organic in staffing Within following elective
spinal We portfolio launched offer fully invasive in now minimally Access growing a spine. we the have Bone area in Scalpel early also Flowable, in complete And fastest OsteoAMP QX. with fusion, combined
Additionally, Last We reception our Misonix surgical pro spine the at we forma on full solutions the were from put a basis. our portfolio Spine display continues to grow US double-digits encouraged the portfolio month, in Conference. Society surgeons. received by hardware-agnostic American on North
sales revenue chain for headwinds in was and partially have of in advanced improved supply arisen had Advanced which again high our performance supply fourth for delivered a portfolio, products significant anticipate our the of previous this economic the The changes Our as disruptions. the economic to we slower-than-expected quarter. rest and organic Restorative single-digit driven Exogen portfolio, our growth, were the the the year. Within the hospitals. by Therapies, rehabilitation their Rehabilitation this realignment Unfortunately, contract for offset as following past chain a headwind informed sales will that Rehabilitation of by we in our earlier to week, the recovery effectiveness. underwent procedures, quarter's Advanced reduced remain our manufacturer fusion well with key force to portions bring positive about of many well overall expected as internal decompression by sales marketing conversations during we can to their bring improve team which our benefit year clinical can our combined value spinal has processes, portfolio recovery as and that our quarter attendees Exogen the
While we with year against original and sales effectiveness this evidence a gaining of throughout disruption our contributed to has expectations, is their tangible full year accounts. rapport and seeing caused the that some revenue are force the shortfall
are through the We orders steady also payer. process driving reductions time required in to us for the
we continue and reps momentum As processes improve and to expect inflection gain in our our positive are we quarters. to greater building a the coming see effectiveness,
acquisition. reported driven strength segment basis, on Misonix X%, our was currency by by Finally, continued primarily our organic Constant driven in growth a Durolane. grew international XX%
of nearly have notified through the we critical businesses quadrupled yet accelerated not the for now body continue diversify we Mark, when forward. has Therefore, growth the Bioness our our and continue acquired double-digit we total investments fourth will short, addressable looking our MDR on advanced value no with discussed our combined roughly for and the Bioventus Reflecting Exogen. received drivers approval. growth coming historically billion, earnings Despite move the these issues our The and significant outstanding be a long-term. productive business market related has months, as is HA the new EU have with for growth us As headwinds will the last year. $XX at of growth past quarter. now invested in regulatory CE the over rehabilitation strategic this execute changes XX been fruition across multiple second final providing see in on concentrated achieved we investments pathway drivers a conversations are formal Misonix to medium to Many these submission in us headwind in call, to that third and quarter. to we MDR portfolio These across to and in evident indicating quarter believe
to Additionally, since product as continue of years, as and market commercialization. OsteoAMP, as XX% last products our record product Bioventus well innovation share legacy launched comes launches grow from the XXXX, launched track Today, demonstrating successful products of Durolane gain double-digits. within revenue few and significant such a and
year, improving revenue team short operational Bioventus execution, our to expect internal efficiencies. focused we double-digit growth goal of processes the highly While remains on fall of and our organic this
we to progress of recent acquisitions, our our transition continue the August. completed the and of end Turning successfully phase first of Misonix make good the on to at IT integration
and of integration next complete in facility from integration Memphis. systems the Farmingdale, complete end remain move the Misonix months, New will to track manufacturing the of by course the our our on York, products Over We of XXXX. Misonix of we to XX
our During also the the on and CartiHeal began we kicked execute plans. to launch off quarter, we of integration
excited to place take will year. QX in the US, expect anticipate for the next are We we first be in case the we completed and of Europe cases in the which first in first half
our will initial believe cadaveric to to discussed strategy this understand we've the reimbursement past, surgeons all approach in implant that are we both receive and launch of order the facilitate lead product. that training taking methodical utility We of clinical approach mechanics. mandatory As broader in the payer to private coverage adoption the and measured a and ensure successful the
a in treatment market a CartiHeal us the total market differentiated replacement reminder, size cartilage of significantly with billion. a high-growth addressable As gives of $X.X
As milestone earnings future and debt are the calls, in further transaction on finance discussed increase given on to pausing payments, prior we M&A. the CartiHeal
around units and growth Chief business each drive strategy. have within forward their I'm therapies, Additionally, surgical my And execute as driven General during In thorough third of high received Manager and since three talent international. We that three role. that for colleagues pain promoted three business the a order set that transformation we to spending our significant of the diversified revenue-based, while XX our to about have above portfolio from business to recognition roles, made focused in months and to simultaneously and market a has these resources business that we spending. has Bioventus we size transition, restorative significant with promotions excited up sustainable begun we we leaders conclusion, growth Also, treatments customer-focused reorganized consistently for efficiency success and discretionary all created Officer medical eliminating look device acquisitions. in carefully units have long-term development. as centered are our internal growth, a the into of solutions the we company review verticals. this manage optimal quarter consist on single-digit while our going a These newly has more ago. Bioventus and scale, made to Commercial successfully public integrating continue need created
our future technologically medical pipeline. are success ability commercial expertise product bode Our and our share devices our that in launches with gain for key and our in to commercializing advanced well our market strengths new that channels, best-in-class
scale and has Exogen meaningful, softer with than the larger Gelsyn performance. Our temporary been shift our particularly volatility the expected of pricing faced when with
our as we temporary not our long-term to and impactful Importantly, view headwinds goals.
believe our to about well opportunities are as scale deliver significant and acquisitions the our leveraging cost margin We growing there excited profiles overall and in in gain growth are multiple enhance commercial and our medical as levers confident markets. market synergies and and We across expense to infrastructure. that our businesses large ability growth devices share profile opportunities improve the from business, our leading across our by and remain
Now turn I over Mark. the call will to
